NCE-1 Intelligence & Market Opportunity

Rezdiffra

Resmetirom

Antimetabolic Disorder

Tablet

Rezdiffra is a prescription medication indicated for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) in individuals with mild to severe hepatic fibrosis. It is used to promote improved liver health in conjunction with a balanced diet and consistent exercise.

Approval Date

14-Mar-24

NCE-1 Date

14-Mar-28

NCE Date

14-Mar-29

Commercial snapshot

Market performance & projections

Revenue ($M)

958

CAGR (%)

0.4161

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1472

2027

2173

2028

2940

2029

3852

2030

4807

2031

5750

2032

6553

Molecule profile

Details & specifications

Molecule

Resmetirom

Innovator

MADRIGAL PHARMACEUTICALS INC

Dosage Form

Tablet

Strength

60 mg, 80 mg, 100 mg

Therapeutic Category

Antimetabolic Disorder

Usage

To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.